Tango Therapeutics Inc
NASDAQ:TNGX
Intrinsic Value
Tango Therapeutics, Inc. operates as a biotechnology company that engages in discovering and delivering precision cancer medicines. [ Read More ]
The intrinsic value of one TNGX stock under the Base Case scenario is 3.5 USD. Compared to the current market price of 7.6 USD, Tango Therapeutics Inc is Overvalued by 54%.
Valuation Backtest
Tango Therapeutics Inc
Run backtest to discover the historical profit from buying and selling TNGX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Tango Therapeutics Inc
Current Assets | 352m |
Cash & Short-Term Investments | 343.6m |
Other Current Assets | 8.4m |
Non-Current Assets | 54.2m |
PP&E | 51.6m |
Other Non-Current Assets | 2.6m |
Current Liabilities | 42.8m |
Accounts Payable | 3.9m |
Accrued Liabilities | 15.8m |
Other Current Liabilities | 23.1m |
Non-Current Liabilities | 99m |
Other Non-Current Liabilities | 99m |
Earnings Waterfall
Tango Therapeutics Inc
Revenue
|
37.2m
USD
|
Operating Expenses
|
-163.4m
USD
|
Operating Income
|
-126.1m
USD
|
Other Expenses
|
14.5m
USD
|
Net Income
|
-111.6m
USD
|
Free Cash Flow Analysis
Tango Therapeutics Inc
TNGX Profitability Score
Profitability Due Diligence
Tango Therapeutics Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
Score
Tango Therapeutics Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.
TNGX Solvency Score
Solvency Due Diligence
Tango Therapeutics Inc's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Score
Tango Therapeutics Inc's solvency score is 62/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TNGX Price Targets Summary
Tango Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for TNGX is 17.92 USD with a low forecast of 16.16 USD and a high forecast of 21 USD.
Ownership
TNGX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
TNGX Price
Tango Therapeutics Inc
Average Annual Return | -12.97% |
Standard Deviation of Annual Returns | 28.59% |
Max Drawdown | -85% |
Market Capitalization | 811.2m USD |
Shares Outstanding | 106 735 000 |
Percentage of Shares Shorted | 18.89% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Tango Therapeutics, Inc. operates as a biotechnology company that engages in discovering and delivering precision cancer medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 91 full-time employees. The company went IPO on 2020-09-03. The firm is engaged in the discovery and development of drugs at tumor suppressor gene loss in patients with unmet medical need. The Company’s product candidates include TNG908 and ubiquitin-specific protease 1 (USP1). Its TNG908, is a potent, selective, synthetic lethal, small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), which is designed to work selectively in cancer cells with an methylthioadenosine phosphorylase (MTAP) deletion. The MTAP-deletion occurs in all human tumors, including cancers with unmet need, such as squamous cell lung, esophageal and bladder cancer. The Company’s USP1, is a synthetic lethal that target for BRCA1-mutant breast, ovarian and prostate cancer. The USP1 treats a patient population for poly (ADP-ribose) polymerase (PARP) inhibitors that are operative against cancers with BRCA1 and BRCA2 mutations.
Contact
IPO
Employees
Officers
The intrinsic value of one TNGX stock under the Base Case scenario is 3.5 USD.
Compared to the current market price of 7.6 USD, Tango Therapeutics Inc is Overvalued by 54%.